Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Avoidance response

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    90 result(s) found for: Avoidance response. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2012-003191-39 Sponsor Protocol Number: Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: The effect of a single-dose of d-cycloserine on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized placebo-controlled trial
    Medical condition: DSM-IV Panic disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003542-68 Sponsor Protocol Number: Start Date*: 2016-01-27
    Sponsor Name:University of Oxford
    Full Title: The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial
    Medical condition: DSM panic disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003104-12 Sponsor Protocol Number: M19VLC Start Date*: 2020-01-14
    Sponsor Name:NKI-AVL
    Full Title: Treatment of locally advanced VULvar CArcinoma in a Neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy
    Medical condition: vulvar carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004776-20 Sponsor Protocol Number: BAP00626 Start Date*: 2006-03-27
    Sponsor Name:Basilea Pharmaceutica Ltd
    Full Title: Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis
    Medical condition: Severe Chronic Hand Dermatitis (CHaD) Refractory to Topical Therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001358-29 Sponsor Protocol Number: ARQ 501-212 Start Date*: 2006-10-30
    Sponsor Name:ARQule Inc.
    Full Title: A Phase 2 Study of ARQ 501 in Combination with Gemcitabine in Adult Patients with Treatment Naive, Unresectable Pancreatic Adenocarcinoma
    Medical condition: Treatment naive, unresectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033611 Pancreatic carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004220-11 Sponsor Protocol Number: APL2-308 Start Date*: 2019-07-23
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001942-15 Sponsor Protocol Number: ARQ 501-208 Start Date*: 2006-11-09
    Sponsor Name:ARQule Inc.
    Full Title: A Phase 2 Study of ARQ 501 in Patients with Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063569 Metastatic squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004028-69 Sponsor Protocol Number: IRIBIL Start Date*: 2016-12-01
    Sponsor Name:Goethe-Universität Frankfurt, PD Fabian Finkelmeier
    Full Title: 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2...
    Medical condition: biliary tract cancer not amedable for curative resection with progressive disease after first-line chematherapy with gemcitabine and cisplatin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002961-32 Sponsor Protocol Number: LP0133-1402 Start Date*: 2021-07-01
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 clinical trial to confirm efficacy and evaluate safety of twice-daily delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adult subjects with moderate...
    Medical condition: Chronic Hand Eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) BE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003171-39 Sponsor Protocol Number: PSD502-PE-004 Start Date*: 2007-12-07
    Sponsor Name:Plethora Solutions Ltd
    Full Title: A phase III, multi-centre, randomized, double-blind, placebo-controlled study, with open-label follow on, to evaluate the efficacy, safety and tolerability of PDS502 in subjects with Premature Ejac...
    Medical condition: Premature Ejaculation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036596 Premature ejaculation PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002960-30 Sponsor Protocol Number: LP0133-1401 Start Date*: 2021-06-15
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 clinical trial to confirm efficacy and evaluate safety of twice-daily delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adult subjects with moderate...
    Medical condition: Chronic Hand Eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002727-32 Sponsor Protocol Number: ARQ 197 - 205 Start Date*: 2007-11-06
    Sponsor Name:ArQule Inc.
    Full Title: A Randomized Phase 2 Study of ARQ 197 versus Gemcitabine in Treatment-naïve Patients with Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
    Medical condition: Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011855-40 Sponsor Protocol Number: OTB109059 Start Date*: 2009-11-26
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Doub...
    Medical condition: Premature ejaculation.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036596 Premature ejaculation LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003343-74 Sponsor Protocol Number: PDS234 Start Date*: 2007-10-30
    Sponsor Name:Academic Medical Center
    Full Title: A methodological investigation to test acute changes in female sexual desire in healthy volunteersand pre- and postmenopausal women diagnosed with hypoactive sexual desiredisordersusing explicit me...
    Medical condition: hypoactive sexual desire disorder in women (HSDD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062641 Female sexual arousal disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000345-38 Sponsor Protocol Number: BAP00089 Start Date*: 2004-07-13
    Sponsor Name:Basilea Pharmaceutica Ltd
    Full Title: Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis
    Medical condition: Severe Chronic Hand Dermatitis (CHaD) Refractory to Topical Therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021621-12 Sponsor Protocol Number: NAI114373 Start Date*: 2010-12-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: NAI114373: A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of ...
    Medical condition: hospitalised adults and adolescents with influenza
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) FR (Completed) GB (Completed) HU (Completed) NL (Completed) CZ (Completed) NO (Completed) DK (Completed) GR (Completed) BE (Completed) PL (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003543-16 Sponsor Protocol Number: LP0133-1528 Start Date*: 2022-07-28
    Sponsor Name:LEO Pharma A/S
    Full Title: A 24 week, randomised, assessor blinded, active-controlled, parallel group, phase 3, 2 arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsu...
    Medical condition: Chronic Hand Eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Ongoing) FR (Completed) AT (Completed) PL (Completed) NO (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004054-28 Sponsor Protocol Number: Panorexia Start Date*: 2020-06-23
    Sponsor Name:Imperial College London
    Full Title: Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study
    Medical condition: Anorexia Nervosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10002646 Anorexia LLT
    20.0 10037175 - Psychiatric disorders 10002649 Anorexia nervosa PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-005512-27 Sponsor Protocol Number: B4Z-EW-LYDY Start Date*: 2007-03-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperac...
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NO (Ongoing) IE (Completed) NL (Not Authorised) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004931-21 Sponsor Protocol Number: BO42162 Start Date*: 2020-10-26
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTUR...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) HU (Completed) FR (Trial now transitioned) PL (Trial now transitioned) GR (Completed) PT (Trial now transitioned) BE (Completed) IE (Prematurely Ended) NL (Trial now transitioned) EE (Completed) LT (Trial now transitioned) IT (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 01 16:54:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA